Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by KVDollarson Jul 20, 2021 3:16pm
133 Views
Post# 33576315

Earnings Forecast - Revenue Potential is 61 million in 2021

Earnings Forecast - Revenue Potential is 61 million in 2021Is blow fish included in this forecast?

when is the next quarterly

12 million cash on hand is that - to accelerate blow fish?

Since they are in Trials 2 for blowfish -- is there a timeline or deadline for that

Who bought the remaining 75 million shares ( when will this come public).

Where do we go next

Do we see potential got back to .50s ?   If so what do we need to get there.

I dont want to talk to bashers -- I want to talk to Longs and PPl genuinely interested in the company and also making a profit..

Lets chat and make some good discussions
<< Previous
Bullboard Posts
Next >>